Literature DB >> 12523914

Cardiovascular disease in type 2 diabetes mellitus: current management guidelines.

Arshag D Mooradian1.   

Abstract

Cardiovascular disease is the most prevalent and detrimental complication of diabetes mellitus. The incidence of cardiovascular mortality in diabetic subjects without a clinical history of previous cardiac events is as high as the incidence in nondiabetic subjects with a history of myocardial infarction. This inordinate increase in the risk of coronary events in diabetic patients is attributed to multiple factors, including glycation and oxidation of proteins and increased prevalence of classic risk factors of coronary disease, such as hypertension, obesity, and dyslipidemia. Despite advances in the management of cardiovascular disease, a large proportion of diabetic subjects continue to have uncontrolled hyperglycemia, hypertension, and dyslipidemia. In addition, certain medical interventions with established efficacy in the general population do not appear to be appropriate for diabetic subjects. Recently published clinical trials of managing coronary risk factors indicate that more stringent goals of therapy should be set for diabetic patients. In this communication, some of these landmark studies are reviewed and some practical guidelines of management are suggested.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12523914     DOI: 10.1001/archinte.163.1.33

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  41 in total

1.  Can diabetes management programs create sustained improvements in disease outcomes?

Authors:  Russell L Rothman; Tom A Elasy
Journal:  CMAJ       Date:  2005-12-06       Impact factor: 8.262

Review 2.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Reducing CVD risk in type 2 DM.

Authors:  Anthony L McCall
Journal:  Curr Diab Rep       Date:  2003-10       Impact factor: 4.810

4.  Low-after-high glucose down-regulated Cx43 in H9c2 cells by autophagy activation via cross-regulation by the PI3K/Akt/mTOR and MEK/ERK1/2 signal pathways.

Authors:  Yaguang Bi; Guangyu Wang; Xiangdong Liu; Meng Wei; Qingyong Zhang
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

5.  Dexamethasone and cardiac potassium currents in the diabetic rat.

Authors:  Yakhin Shimoni
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

Review 6.  Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm.

Authors:  Arshag D Mooradian
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

7.  The incremental costs of recommended therapy versus real world therapy in type 2 diabetes patients.

Authors:  C Crivera; D C Suh; E S Huang; E Cagliero; R W Grant; L Vo; H C Shin; J B Meigs
Journal:  Curr Med Res Opin       Date:  2006-11       Impact factor: 2.580

Review 8.  Targeting hypertension in patients with cardiorenal metabolic syndrome.

Authors:  Edward Rojas; Manuel Velasco; Valmore Bermúdez; Zafar Israili; Peter Bolli
Journal:  Curr Hypertens Rep       Date:  2012-10       Impact factor: 5.369

Review 9.  Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers?

Authors:  Wei X Lu; Jay Lakkis; Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2003-06       Impact factor: 5.369

Review 10.  Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management.

Authors:  Joe M Chehade; Margaret Gladysz; Arshag D Mooradian
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.